| Literature DB >> 35117522 |
Yi-Hua Shi1, Tian-Fu Wen1, De-Shuang Xiao1, Ling-Bo Dai1, Jun Song1.
Abstract
BACKGROUND: MicroRNAs (miRNAs) were aberrantly regulated in cancers, showing their roles as novel classes of oncogenes and tumor suppressors. Hence, an integrated method was introduced in this study to explore miRNA targets for hepatocellular carcinoma (HCC).Entities:
Keywords: Hepatocellular carcinoma (HCC); integrated method; microRNA (miRNA); target
Year: 2020 PMID: 35117522 PMCID: PMC8798414 DOI: 10.21037/tcr.2020.02.46
Source DB: PubMed Journal: Transl Cancer Res ISSN: 2218-676X Impact factor: 1.241
Figure 1The flow diagram for the inference of miRNA targets. PCC, Pearson’s correlation coefficient; IDA, inference method; TCGA, The Cancer Genome Atlas; KEGG, Kyoto Encyclopedia of Genes and Genomes.
Highly confident miRNA-mRNA interaction
| ID | mRNA | miRNA | z-score |
|---|---|---|---|
| 1 |
| hsa-mir-338 | 4,468 |
| 2 |
| hsa-mir-203 | 4,434 |
| 3 |
| hsa-mir-505 | 4,391 |
| 4 |
| hsa-mir-1180 | 4,308 |
| 5 |
| hsa-mir-185 | 4,297 |
| 6 |
| hsa-mir-30a | 4,272 |
| 7 |
| hsa-mir-339 | 4,241 |
| 8 |
| hsa-mir-32 | 4,236 |
| 9 |
| hsa-mir-653 | 4,219 |
| 10 |
| hsa-mir-152 | 4,200 |
| 11 |
| hsa-mir-504 | 4,187 |
| 12 |
| hsa-mir-642a | 4,168 |
| 13 |
| hsa-mir-149 | 4,105 |
| 14 |
| hsa-mir-196b | 4,063 |
| 15 |
| hsa-mir-10b | 4,001 |
| 16 |
| hsa-mir-1911 | 3,974 |
| 17 |
| hsa-mir-483 | 3,881 |
| 18 |
| hsa-mir-2355 | 3,863 |
| 19 |
| hsa-mir-335 | 3,847 |
| 20 |
| hsa-mir-3200 | 3,809 |
| 21 |
| hsa-mir-139 | 3,794 |
| 22 |
| hsa-mir-582 | 3,766 |
| 23 |
| hsa-mir-151 | 3,735 |
| 24 |
| hsa-mir-153- | 3,682 |
| 25 |
| hsa-mir-184 | 3,657 |
| 26 |
| hsa-mir-101-2 | 3,584 |
| 27 |
| hsa-mir-1976 | 3,560 |
| 28 |
| hsa-mir-3614 | 3,548 |
| 29 |
| hsa-mir-766 | 3,504 |
| 30 |
| hsa-mir-584 | 3,499 |
| 31 |
| hsa-mir-33b | 3,485 |
| 32 |
| hsa-mir-652 | 3,468 |
| 33 |
| hsa-mir-211 | 3,461 |
| 34 |
| hsa-mir-186 | 3,457 |
| 35 |
| hsa-mir-577 | 3,442 |
| 36 |
| hsa-mir-1270-2 | 3,423 |
| 37 |
| hsa-mir-125b-2 | 3,419 |
| 38 |
| hsa-mir-664 | 3,406 |
| 39 |
| hsa-mir-708 | 3,376 |
| 40 |
| hsa-mir-1251 | 3,364 |
| 41 |
| hsa-mir-942 | 3,351 |
| 42 |
| hsa-mir-490 | 3,307 |
| 43 |
| hsa-mir-328 | 3,240 |
| 44 |
| hsa-mir-219-1 | 3,197 |
| 45 |
| hsa-mir-454 | 3,007 |
| 46 |
| hsa-mir-598 | 2,972 |
| 47 |
| hsa-mir-505 | 2,748 |
| 48 |
| hsa-mir-196b | 2,680 |
| 49 |
| hsa-mir-10b | 2,549 |
| 50 | hsa-mir-155 | 2,308 |
miRNA targets with predicted times ≥10
| Targets | Times | miRNAs |
|---|---|---|
|
| 29 | hsa-mir-127, hsa-mir-134, hsa-mir-154, hsa-mir-299, hsa-mir-323, hsa-mir-323b, hsa-mir-337, hsa-mir-369, hsa-mir-370, hsa-mir-376a-2, hsa-mir-376b, hsa-mir-377, hsa-mir-379, hsa-mir-381, hsa-mir-382, hsa-mir-409, hsa-mir-410, hsa-mir-411, hsa-mir-412, hsa-mir-431, hsa-mir-432, hsa-mir-433, hsa-mir-485, hsa-mir-487a, hsa-mir-493, hsa-mir-494, hsa-mir-539, hsa-mir-541, hsa-mir-889 |
|
| 12 | hsa-mir-127, hsa-mir-299, hsa-mir-337, hsa-mir-370, hsa-mir-377, hsa-mir-379, hsa-mir-381, hsa-mir-382, hsa-mir-409, hsa-mir-411, hsa-mir-433, hsa-mir-494 |
|
| 12 | hsa-mir-299, hsa-mir-323, hsa-mir-323b, hsa-mir-369, hsa-mir-370, hsa-mir-377, hsa-mir-409, hsa-mir-432, hsa-mir-433, hsa-mir-485, hsa-mir-493, hsa-mir-889 |
|
| 11 | hsa-mir-125a, hsa-mir-136, hsa-mir-181c, hsa-mir-199b, hsa-mir-299, hsa-mir-377, hsa-mir-381, hsa-mir-409, hsa-mir-411, hsa-mir-598, hsa-mir-758 |
|
| 10 | hsa-mir-10a, hsa-mir-1247, hsa-mir-125a, hsa-mir-136, hsa-mir-153-2, hsa-mir-199b, hsa-mir-214, hsa-mir-376b, hsa-mir-376c, hsa-mir-758 |
|
| 10 | hsa-mir-1287, hsa-mir-299, hsa-mir-376b, hsa-mir-409, hsa-mir-485, hsa-mir-487a, hsa-mir-493, hsa-mir-496, hsa-mir-887, hsa-mir-99b |
KEGG pathways for target genes in top 1,000 miRNA-mRNA interactions
| ID | Pathway | P value |
|---|---|---|
| 1 | Complement and coagulation cascades | 2.05E-08 |
| 2 | Bile secretion | 4.36E-05 |
| 3 | Primary immunodeficiency | 7.13E-04 |
| 4 | Arginine and proline metabolism | 2.25E-03 |
| 5 | Alanine aspartate and glutamate metabolism | 5.02E-03 |
| 6 | Cytokine-cytokine receptor interaction | 9.22E-03 |
| 7 | Drug metabolism—cytochrome P450 | 1.41E-02 |
| 8 | Phenylalanine metabolism | 1.84E-02 |
| 9 | Metabolism of xenobiotics by cytochrome P450 | 2.83E-02 |
| 10 | Pancreatic secretion | 3.07E-02 |
| 11 | Histidine metabolism | 3.16E-02 |
| 12 | Drug metabolism—other enzymes | 3.46E-02 |
| 13 | Cell adhesion molecules (CAMs) | 3.53E-02 |
| 14 | Peroxisome | 3.73E-02 |
| 15 | Pentose and glucuronate interconversions | 3.83E-02 |
| 16 | Phenylalanine tyrosine and tryptophan biosynthesis | 3.84E-02 |
| 17 | Proximal tubule bicarbonate reclamation | 4.15E-02 |
| 18 | Fat digestion and absorption | 4.16E-02 |
| 19 | Vascular smooth muscle contraction | 4.19E-02 |
| 20 | Fructose and mannose metabolism | 4.23E-02 |
| 21 | Ether lipid metabolism | 4.29E-02 |
| 22 | Hematopoietic cell lineage | 4.38E-02 |
| 23 | Ascorbate and aldarate metabolism | 4.59E-02 |
| 24 | Primary bile acid biosynthesis | 4.69E-02 |
| 25 | Glycolysis/gluconeogenesis | 4.71E-02 |
| 26 | T cell receptor signaling pathway | 4.94E-02 |
KEGG, Kyoto Encyclopedia of Genes and Genomes.